Gene-Edited immune cells offer new hope for kids with relapsed leukemia
NCT ID NCT05942599
First seen Jan 18, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This early-phase study tests a new therapy called BE CAR-33 in 10 children (6 months to 16 years) with relapsed acute myeloid leukemia. The therapy uses donor immune cells that are gene-edited to better target and kill leukemia cells. The main goal is to check safety and see if it can clear leukemia before a planned bone marrow transplant, which aims to prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Great Ormond Street Hospital for Children
London, WC1N3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.